Alkermes Plc - ESG Rating & Company Profile powered by AI
This page is a zero-cost Sustainability report covering Alkermes Plc. This ESG score covers seventeen UN Sustainable Development Goals including: 'Zero Hunger', 'Industry, Innovation & Infrastructure' and 'Life on Land'. The article includes a Q&A table about Alkermes Plc.
Alkermes Plc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 7.5; made up of an environmental score of 8.0, social score of 7.0 and governance score of 7.0.
7.5
High ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Novartis AG | 9.2 | High |
| 2 | Daiichi Sankyo Co Ltd | 8.9 | High |
| 209 | WuXi AppTec Co Ltd | 7.6 | High |
| 209 | Waters Corp | 7.6 | High |
| 256 | Alkermes Plc | 7.5 | High |
| 256 | Acorda Therapeutics Inc | 7.5 | High |
| 256 | Athira Pharma Inc | 7.5 | High |
| ... | ... | ... | |
| 2749 | Xynomic Pharmaceuticals Holdings Inc | 0.0 | Low |
| 2749 | Zyden Gentec Ltd | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Alkermes Plc have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Alkermes Plc disclose current and historical energy intensity?
Sign up for free to unlockDoes Alkermes Plc report the average age of the workforce?
Sign up for free to unlockDoes Alkermes Plc reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Alkermes Plc disclose its ethnicity pay gap?
Sign up for free to unlockDoes Alkermes Plc disclose cybersecurity risks?
Sign up for free to unlockDoes Alkermes Plc offer flexible work?
Sign up for free to unlockDoes Alkermes Plc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Alkermes Plc disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Alkermes Plc conduct supply chain audits?
Sign up for free to unlockDoes Alkermes Plc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Alkermes Plc conduct 360 degree staff reviews?
Sign up for free to unlockDoes Alkermes Plc disclose the individual responsible for D&I?
Sign up for free to unlockDoes Alkermes Plc disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Alkermes Plc disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Alkermes Plc disclose water use targets?
Sign up for free to unlockDoes Alkermes Plc have careers partnerships with academic institutions?
Sign up for free to unlockDid Alkermes Plc have a product recall in the last two years?
Sign up for free to unlockDoes Alkermes Plc disclose incidents of discrimination?
Sign up for free to unlockDoes Alkermes Plc allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Alkermes Plc issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Alkermes Plc disclose parental leave metrics?
Sign up for free to unlockDoes Alkermes Plc disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Alkermes Plc disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Alkermes Plc disclose the pay ratio of women to men?
Sign up for free to unlockDoes Alkermes Plc support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Alkermes Plc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Alkermes Plc reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Alkermes Plc involved in embryonic stem cell research?
Sign up for free to unlockDoes Alkermes Plc disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Alkermes Plc disclose its waste policy?
Sign up for free to unlockDoes Alkermes Plc report according to TCFD requirements?
Sign up for free to unlockDoes Alkermes Plc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Alkermes Plc disclose energy use targets?
Sign up for free to unlockDoes Alkermes Plc disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Alkermes Plc have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Alkermes Plc
These potential risks are based on the size, segment and geographies of the company.
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL for the treatment of alcohol and prevention of opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA to treat schizophrenia and schizoaffective; and VUMERITY for the treatment of relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting and active secondary progressive diseases. The company is also developing LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and nemvaleukin alfa, an engineered fusion protein to expand tumor-killing immune cells and to avoid the activation of immunosuppressive cells. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.